Wire · operational-macro
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
The FDA granted final approval to Bravnetsa (lutetium Lu 177 dotatate) as a bioequivalent and therapeutically equivalent biosimilar to Lutathera for treating adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking the first radiopharmaceutical approved through the ANDA pathway as equivalent to Lutathera.
This Wire brief sits within Fusion42's coverage of Health: Biotech.
◆ ◆ The Wire takeaway
You must factor in how Bravnetsa's FDA approval opens a new FDA-validated biosimilar route in radiopharmaceutical oncology that can lower treatment costs and broaden patient access. This is a prime moment to engage providers and plans working on GEP-NET therapies.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics